组蛋白去乙酰化酶抑制剂治疗血液系统恶性疾病的研究进展  

Advances in research of histone deacetylase inhibitors in treatment of hematological diseases

作　　者：郑丹钿 谭获[1] Zheng Dantian;Tan Huo(Department of Hematology,First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510230,Guangdong Province,China)

机构地区：[1]广州医科大学附属第一医院血液科,510230

出　　处：《国际输血及血液学杂志》2018年第6期530-534,共5页International Journal of Blood Transfusion and Hematology

基　　金：广东省自然科学基金项目(2016A030313598).

摘　　要：组蛋白乙酰转移酶(HAT)与组蛋白去乙酰化酶(HDAC)参与细胞周期调控、细胞增殖和存活、细胞分化、细胞代谢、蛋白质运输、DNA修复和血管生成过程,二者失衡与某些肿瘤的发生相关。因此,针对HDAC家族的各类靶向药物均可能对肿瘤治疗有效。笔者通过对西达苯胺与其他组蛋白去乙酰化酶抑制剂(HDACi)在治疗淋巴瘤、白血病、骨髓增生异常综合征(MDS)、多发性骨髓瘤(MM)等血液系统恶性疾病的研究进展进行综述,旨在将HDACi更好地运用于临床实践中。Histone acetyltransferase (HAT) and histone deacetylase (HDAC) are involved in cell cycle regulation, cell proliferation and survival, cell differentiation, cell metabolism, protein trafficking, DNA repair and angiogenesis. Imbalance of HAT and HDAC is associated with the occurrence of some tumors. Therefore, various targeted drugs targeting the HDAC family may be effective for tumor treatment. This article will review the progress of chidamide, compared with the other histone deacetylase inhibitor (HDACi), in the treatment of hematological diseases such as lymphoma, leukemia, myelodysplastic syndrome (MDS), and multiple myeloma (MM). And these new drugs can serve the clinical practice in a better way.

关 键 词：组蛋白脱乙酰基酶抑制剂 血液肿瘤 分子靶向治疗 西达苯胺 治疗 

分 类 号：R733[医药卫生—肿瘤]